Top DOJ Atty Outlines Pharma Fraud Enforcement

By Jeff Overley (January 29, 2014, 7:03 PM EST) -- The U.S. Department of Justice's Civil Division chief on Wednesday delivered a stern message to pharmaceutical industry leaders about fraud enforcement, promising expanded use of intrusive oversight agreements and continued punishment of off-label marketing.

Assistant Attorney General Stuart F. Delery, speaking at the CBI Pharmaceutical Compliance Congress in Washington, D.C., outlined the aggressive posture while also vowing to be lenient with manufacturers when they're candid about potentially fraudulent activities, according to prepared remarks released by the DOJ.

One section of Delery's speech focused on making so-called corporate integrity agreements more punitive. As one example, the assistant attorney general cited a 2012...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!